Combinations of Sacituzumab govitecan plus enfortumab vedotin and pembrolizumab for metastatic urothelial carcinoma: the Double Antibody Drug conjugate (DAD) and Double Antibody Drug Conjugate with Immunotherapy Phase I/II trial